Xtant Medical Holdings, Inc. — fact timeline

Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2026 results: revenue $20.9 million, net income net loss was $3.1 million. Guidance raised.

“conditions, today reported financial and operating results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights ● Generated total revenue of $20.9 million for the first quarter of 2026, as compared to $32.9 million for the first quarter of 2025. The decline in revenue relates primarily to the sale of assets and businesses to”

Xtant Medical Holdings, Inc. reported Full Year 2025 results: revenue $134.0 million, net income $5.0 million, EPS $0.03 per diluted share.

“and may be different from non-GAAP finan --- EX-99.1 (EX-99.1) --- Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 31, 2025 with an”

Xtant Medical Holdings, Inc. reported Fourth Quarter 2025 results: revenue $32.4 million, net income $0.1 million.

“Fourth quarter 2025 revenue grew 3% to $32.4 million, compared to $31.5 million for the same period in 2024.”

Xtant Medical Holdings, Inc. faced acceleration on term loan of approximately $8.0 million with MidCap Financial Trust.

“approximately $8.0 million of the net cash proceeds received by the Company from the Divestitures (including previous deposits received) was used to prepay a portion of the Company’s term loan with MidCap, resulting in $14.4 million remaining outstanding under the term loan as of December 1, 2025, of which up to an additional $1.6 million will be required to be prepaid if and when the Companion Spine Note is repaid by Companion Spine.”

Xtant Medical Holdings, Inc. completed a disposition involving Companion Spine SAS for $1.7 million (closed 2025-12-01).

“Companion Spine (the “Paradigm Agreement” and together with the Coflex/CoFix Agreement, the “Divestiture Agreements”). The total purchase price of the Paradigm Divestiture was $1.7 million (the “Paradigm Purchase Price”), which was paid to the Company in cash at the closing of the Paradigm Divestiture. The Paradigm Purchase Price is subject to future adjustments”

Xtant Medical Holdings, Inc. completed a disposition involving Companion Spine, LLC and one of its affiliates, Companion Spine SAS for $17.5 million (closed 2025-12-01).

“Asset Purchase Agreement dated July 7, 2025 between the Seller and Companion Spine (the “Coflex/CoFix Agreement”). The total purchase price of the Coflex/CoFix Divestiture was $17.5 million (subject to a closing inventory valuation adjustment set forth in the Coflex/CoFix Agreement) (the “Coflex/CoFix Purchase Price”). Of the total purchase price, an aggregate of”

Xtant Medical Holdings, Inc. underwent a change of control involving Nantahala Capital Management, LLC for approximately $30.7 million (closed 2025-04-15).

“Pursuant to the Transaction, as described in the Introductory Note hereto, which is incorporated by reference into this Item 5.01, the Purchasers completed the acquisition of the Shares from the Sellers, constituting 52.5% of the Common Stock outstanding as of April 15, 2025 for approximately $30.7 million, which the Company believes was funded out of the Purchasers’ personal funds. The consummation of the Transaction resulted in a change in control of the Company, as a result of which the Sellers own no shares of Common Stock and Nantahala gained effective control of the Company by virtue of holding approximately 49.1% of the Company’s issued and outstanding Common Stock and being the largest stockholder of the Company.”

Xtant Medical Holdings, Inc. reported full year 2024 results: revenue $116 million to $120 million. Guidance raised.

“Xtant Medical raises its expectation for full year 2024 revenue to $116 million to $120 million, up from the Company’s prior guidance of $112 million to $116 million.”

Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $27.9 million, net income $4.3 million, or $0.03 per share, EPS $0.03 per share. Guidance raised.

“treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights ● Revenue of $27.9 million, up 55%, compared to the prior year quarter ● Gross margin of 62.1%, up 340 basis points, compared to the prior year quarter ● Net loss of $4.4 million compared to $2.1 million”

Xtant Medical Holdings, Inc. amended revolving credit of up to $17,000,000 with MidCap Funding IV Trust at SOFR Interest Rate plus 4.50% maturing March 1, 2029.

“and lenders from time to time party thereto. The Term Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of $17,000,000, which was previously funded under the Prior Term Credit Agreement, and an additional $10,000,000 tranche available solely at the discretion of MidCap Financial Trust and the”

Xtant Medical Holdings, Inc. amended credit facility of $17,000,000 with MidCap Financial Trust at SOFR Interest Rate plus 6.50% maturing March 1, 2029.

“and lenders from time to time party thereto. The Term Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of $17,000,000, which was previously funded under the Prior Term Credit Agreement, and an additional $10,000,000 tranche available solely at the discretion of MidCap Financial Trust and the”

Xtant Medical Holdings, Inc. amended Credit Agreements with MidCap Financial Trust and MidCap Funding IV Trust valued at $17,000,000 term facility and $17,000,000 revolving facility (effective 2024-03-07).

“On March 7, 2024 (the “Closing Date”), Xtant Medical Holdings, Inc. (the “Company”), as guarantor, and certain of its subsidiaries, Xtant Medical, Inc., Bacterin International, Inc., X-spine Systems, Inc. and Surgalign SPV, Inc., as borrowers (collectively, the “Borrowers”), entered into (i) an Amended and Restated Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) with MidCap Financial Trust, in its capacity as agent, and the lenders from time to time party thereto, and (ii) an Amended and Restated Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement” and, together with the Term Credit Agreement, the “Credit Agreements”) with MidCap Funding IV Trust, in its capacity as agent, and the lenders from time to time party thereto.”

Xtant Medical Holdings, Inc. updated its full year 2023 guidance (raised).

“Xtant Medical raises its expectation for full year 2023 revenue to $88 million to $91 million, up from the Company’s prior guidance of $75 million to $77 million.”

Xtant Medical Holdings, Inc. reported third quarter ended September 30, 2023 results: revenue $25.0 million, net income $9.2 million, or $0.07 per share, EPS $0.07 per share. Guidance raised.

“Xtant Medical Announces Record Third Quarter Revenue of $25 Million Raises 2023 Annual Revenue Guidance to $88 Million - $91 Million”

Xtant Medical Holdings, Inc. dismissed Plante & Moran, PLLC as its auditor.

“dismissed Plante & Moran, PLLC (“Plante Moran”), as the Company’s independent registered public accounting firm, subject to Grant Thornton LLP’s standard client acceptance procedures, which were completed on August 18, 2023.”

Xtant Medical Holdings, Inc. engaged Grant Thornton LLP as its auditor.

“On August 15, 2023, the Audit Committee of the Board of Directors of Xtant Medical Holdings, Inc. (the “Company”) appointed Grant Thornton LLP (“Grant Thornton”) as the Company’s independent registered public accounting firm”

Xtant Medical Holdings, Inc. completed an acquisition involving Surgalign Holdings, Inc. for $5 million (closed 2023-08-10).

“Seller’s bankruptcy proceedings. The Bankruptcy Court issued a Sale Order on August 9, 2023 approving and authorizing the Transaction. The Company funded the purchase price of $5 million, plus Liabilities, with cash on hand. The foregoing summary of the Asset Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of”

Xtant Medical Holdings, Inc. amended Limited Consent and Amendment No. 4 to Credit, Security and Guarantee Agreement (Term Loan) with MidCap Financial Trust (effective 2023-08-10).

“On August 10, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), entered into a Limited Consent and Amendment No. 4 to Credit, Security and Guarantee Agreement (Term Loan) (“Term Amendment No. 4"), which amends the Credit, Security and Guarantee Agreement (Term Loan) by and among the Company, as guarantor, and its U.S. subsidiaries, as borrowers, MidCap Financial Trust, as agent, and the financial institutions party thereto (as amended, the “Term Credit Agreement”), and a Limited Consent and Amendment No. 4 to Credit, Security and Guarantee Agreement (Revolving Loan) (“Revolving Amendment No. 4"”

Xtant Medical Holdings, Inc. reported full year 2023 results: revenue $75 million to $77 million. Guidance raised.

“Xtant Medical raises its expectation for full year 2023 revenue to $75 million to $77 million, up from the Company's prior guidance of $73 million to $75 million.”

Xtant Medical Holdings, Inc. reported second quarter ended June 30, 2023 results: net income -$2.2 million, EPS -$0.02.

“Second quarter 2023 revenue grew 32%, representing organic growth of 14% plus an 18% increase from products added in the acquisition of the Coflex and CoFix lines, to $20.2 million, compared to $15.3 million for the same period in 2022.”

Xtant Medical Holdings, Inc.: Stockholders approved three charter amendments: (1) requiring supermajority director vote to fix number of directors above seven; (2) eliminating/limiting officer personal liability per Delaware law; (3) amending exclusive forum provision (effective 2023-07-26).

“At the Company’s 2023 annual meeting of stockholders held on July 26, 2023, the Company’s stockholders approved the following three amendments to the Company’s Amended and Restated Certificate of Incorporation, as amended (collectively, the “Charter Amendments”): ● an amendment requiring a supermajority director vote to fix the number of directors of the Company at more than seven; ● an amendment to eliminate or limit the personal liability of the Company’s officers to the extent permitted by recent amendments to the Delaware General Corporation Law; and ● an amendment to amend the Company’s exclusive forum provision.”

Xtant Medical Holdings, Inc. shareholders approved Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan at the 2023-07-26 meeting.

“Proposal Seven - The Company's stockholders approved the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan by the following final voting results:”

Xtant Medical Holdings, Inc. shareholders approved Charter Amendment amending exclusive forum provision at the 2023-07-26 meeting.

“Proposal Six - The Company's stockholders approved the Charter Amendment amending the Company's exclusive forum provision by the following final voting results:”

Xtant Medical Holdings, Inc. shareholders approved Charter Amendment requiring supermajority director vote to fix number of directors at more than seven at the 2023-07-26 meeting.

“Proposal Five - The Company's stockholders approved the Charter Amendment requiring a supermajority director vote to fix the number of directors of the Company at more than seven by the following final voting results:”

Xtant Medical Holdings, Inc. shareholders approved Charter Amendment eliminating or limiting personal liability of officers at the 2023-07-26 meeting.

“Proposal Four - The Company's stockholders approved the Charter Amendment eliminating or limiting the personal liability of the Company's officers to the extent permitted by recent amendments to the Delaware General Corporation Law by the following final voting results:”

Xtant Medical Holdings, Inc. shareholders approved Advisory approval of executive compensation at the 2023-07-26 meeting.

“Proposal Three - The Company's stockholders approved, on an advisory basis, the compensation of the Company's executive officers named in the 2023 Proxy Statement by the following final voting results:”

Xtant Medical Holdings, Inc. shareholders approved Ratification of appointment of Plante & Moran, PLLC as independent registered public accounting firm for 2023 at the 2023-07-26 meeting.

“Proposal Two - The Company's stockholders ratified the appointment of Plante & Moran, PLLC as the Company's independent registered public accounting firm for the year ending December 31, 2023 by the following final voting results:”

Xtant Medical Holdings, Inc. shareholders approved Election of six director nominees at the 2023-07-26 meeting.

“Proposal One - The six director nominees proposed by the Board were elected to serve as members of the Board until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified by the following final voting results:”

Xtant Medical Holdings, Inc. amended Asset Purchase Agreement with Surgalign Holdings, Inc. valued at $5 million in cash (effective 2023-07-10).

“On July 10, 2023, the Company and the Seller entered into a First Amendment to Asset Purchase Agreement (the “Amendment”).”

Xtant Medical Holdings, Inc. updated its the quarter ended June 30, 2023 guidance (initiated).

“On July 3, 2023, the Company made available an investor presentation (the “Investor Presentation”), which contains certain financial guidance, including for the quarter ended June 30, 2023”

Xtant Medical Holdings, Inc. entered into Placement Agent Agreement with Craig-Hallum Capital Group LLC.

“the Company entered into an engagement letter with Craig-Hallum Capital Group LLC (the “Placement Agent”) pursuant to which the Placement Agent is serving as the Company’s placement agent in connection with the Private Placement (the “Placement Agent Agreement”).”

Xtant Medical Holdings, Inc. entered into Securities Purchase Agreement with accredited investors (the "Investors") valued at $15.0 million (effective 2023-07-03).

“On July 3, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited investors (the “Investors”), pursuant to which the Company agreed to issue an aggregate of 20,000,000 shares (the “Shares”) of common stock, par value $0.000001 per share (the “Common Stock”), in a private placement (the “Private Placement”), at a per Share purchase price of $0.75.”

Xtant Medical Holdings, Inc. entered into Asset Purchase Agreement with Surgalign Holdings, Inc. valued at $5 million (effective 2023-06-18).

“On June 18, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Surgalign Holdings, Inc., a Delaware corporation (the “Seller”), pursuant to which, subject to the terms and conditions set forth in the Asset Purchase Agreement, the Company agreed to acquire certain assets of the Seller and its subsidiaries on an as-is, where-is basis, including specified inventory, intellectual property and intellectual property rights, contracts, equipment and other personal property, records, all outstanding equity securities of the Seller’s international subsidiaries, and intangibles related to the business of designing, developing and manufacturing hardware medical technology and distributing biologics medical technology, as conducted by the Seller and its subsidiaries (collectively, the “Assets”), and assume certain specified liabilities of the Seller and its subsidiaries (collectively, the “Liabi”

Xtant Medical Holdings, Inc.: Adopted Third Amended and Restated Bylaws incorporating amendments including universal proxy rules and DGCL updates (effective 2023-06-01).

“On May 16, 2023, the Board of Directors (the “Board”) of Xtant Medical Holdings, Inc. (the “Company”) approved and adopted Third Amended and Restated Bylaws (the “Amended and Restated Bylaws”) incorporating certain amendments, including amendments in response to the new universal proxy rules promulgated by the Securities and Exchange Commission (the “SEC”) and recent amendments to the Delaware General Corporation Law (the “DGCL”). The Amended and Restated Bylaws will become effective June 1, 2023.”

Lori D. Mitchell-Keller was elected as Director at Xtant Medical Holdings, Inc..

“On May 16, 2023, the Board of Directors (the “Board”) of Xtant Medical Holdings, Inc. (the “Company”) elected Lori D. Mitchell-Keller to the Board, effective immediately.”

Xtant Medical Holdings, Inc. reported full year 2023 results: revenue $73 million to $75 million. Guidance initiated.

“Xtant Medical expects full year 2023 revenue of $73 million to $75 million, representing annual growth of approximately 26% to 29% compared to full year 2022.”

Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $17.9 million, net income $2.1 million, or $0.02 per share, EPS $0.02 per share.

“2023 Financial Results First quarter 2023 revenue grew 38%, including organic growth of 29% and a 9% contribution from the acquisition of the Coflex and CoFix product lines, to $17.9 million, compared to $13.0 million for the same period in 2022. The increase in revenue was attributed primarily to greater independent agent sales and sales from the recently acquired”

Matthew Rizzo resigned as Director at Xtant Medical Holdings, Inc..

“Michael Eggenberg and Matthew Rizzo resigned as directors of the Company, effective immediately upon the date in which the Board elected Jonn R. Beeson as a director.”

Michael Eggenberg resigned as Director at Xtant Medical Holdings, Inc..

“Michael Eggenberg and Matthew Rizzo resigned as directors of the Company, effective immediately upon the date in which the Board elected Jonn R. Beeson as a director.”

Jonn R. Beeson was elected as Director at Xtant Medical Holdings, Inc..

“On May 1, 2023, the Board of Directors (the “Board”) of Xtant Medical Holdings, Inc. (the “Company”) elected Jonn R. Beeson to the Board, effective immediately.”

Xtant Medical Holdings, Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $15.3 million, net income $0.02 per share, EPS $0.02 per share.

“network, all of which are core focus areas to our long-term growth strategy.” Fourth Quarter and Full Year 2022 Financial Results Fourth quarter 2022 revenue grew 9% to $15.3 million, compared to $14.0 million for the same quarter in 2021. Full year 2022 revenue was $58.0 million, compared to $55.3 million for 2021. The increase in revenue was largely”

Xtant Medical Holdings, Inc. completed an acquisition involving Surgalign SPV, Inc. for $17.0 million in cash (closed 2023-02-28).

“Seller agreed to sell to the Company, and the Company agreed to purchase from Seller, all of the issued and outstanding shares of common stock of Surgalign SPV, which shares constitute all of the outstanding equity of Surgalign SPV, for an aggregate purchase price of $17.0 million in cash (the “Purchase Price”). The closing contemplated by the Equity Purchase Agreement occurred on February 28, 2023 (the “Closing”).”

Xtant Medical Holdings, Inc. amended credit facility of additional $5.0 million with MidCap Financial Trust at SOFR rate plus the applicable margin of 7.00% maturing May 1, 2026.

“On February 28, 2023, the Company entered into the Term Amendment No. 3, which provided an additional $5.0 million under the Term Credit Agreement”

Xtant Medical Holdings, Inc. amended Amendment No. 3 to Credit, Security and Guarantee Agreement (Revolving Loan) with MidCap Funding IV Trust (as agent) and the financial institutions party thereto (effective 2023-02-28).

“In addition to the Term Amendment No. 3., the Company entered into an Amendment No. 3 to Credit, Security and Guarantee Agreement (Revolving Loan) (“Revolving Amendment No. 3” and, together with the Term Amendment No. 3, the “Amendments No. 3”), which amends the Credit, Security and Guarantee Agreement (Revolving Loan), by and among the Company, as guarantor, and its subsidiaries, as borrowers, and MidCap Funding IV Trust, as agent, and the financial institutions party thereto (the “Revolving Credit Agreement”).”

Xtant Medical Holdings, Inc. amended Amendment No. 3 to Credit, Security and Guarantee Agreement (Term Loan) with MidCap Financial Trust (as agent) and the financial institutions party thereto (effective 2023-02-28).

“The Company funded the Purchase Price with cash on hand and approximately $5.0 million of indebtedness incurred under its Credit, Security and Guarantee Agreement (Term Loan) by and among the Company, as guarantor, and its subsidiaries, as borrowers, MidCap Financial Trust, as agent, and the financial institutions party thereto (the “Term Credit Agreement”), which was amended on February 28, 2023 pursuant to an Amendment No. 3 to Credit, Security and Guarantee Agreement (Term Loan) (“Term Amendment No. 3”) to provide such funding.”

Xtant Medical Holdings, Inc. entered into Transition Services Agreement with Surgalign SPV, Inc. and Seller (effective 2023-02-28).

“In conjunction with the Equity Purchase Agreement, on February 28, 2023, the Company entered into a Transition Services Agreement (“Transition Services Agreement”) with Surgalign SVP and Seller, whereby Seller agreed to provide, or cause to be provided, to the Company and its affiliates on and after the effective date of the Equity Purchase Agreement, after giving effect to the Closing, certain transitional services related to the transition of the Coflex Business.”

Xtant Medical Holdings, Inc. entered into Equity Purchase Agreement with Surgalign SPV, Inc., Surgalign Spine Technologies, Inc. (Seller), and Surgalign Holdings, Inc. valued at $17.0 million (effective 2023-02-28).

“On February 28, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), entered into an Equity Purchase Agreement (the “Equity Purchase Agreement”) with Surgalign SPV, Inc. (“Surgalign SPV”), a Delaware corporation and wholly owned subsidiary of Surgalign Spine Technologies, Inc., a Delaware corporation (“Seller”), Seller and Surgalign Holdings, Inc., a Delaware corporation, pursuant to which Seller agreed to sell to the Company, and the Company agreed to purchase from Seller, all of the issued and outstanding shares of common stock of Surgalign SPV, which shares constitute all of the outstanding equity of Surgalign SPV, for an aggregate purchase price of $17.0 million in cash (the “Purchase Price”).”

Mark A. Schallenberger was appointed as Chief Operations Officer at Xtant Medical Holdings, Inc..

“On January 9, 2023, Xtant Medical Holdings, Inc. (the “Company”) announced the appointment of Mark A. Schallenberger as Chief Operations Officer, effective as of January 16, 2023.”

Xtant Medical Holdings, Inc. reported third quarter ended September 30, 2022 results: revenue $14.5 million, net income $2.4 million, EPS $0.03 per share.

“by the first quarter of 2023 enabling our team to take advantage of the robust demand environment.” Third Quarter 2022 Financial Results Third quarter 2022 revenue was $14.5 million, compared to $13.8 million for the same quarter in 2021. The increase in revenue was largely attributable to introductions of new products. Gross margin for the third quarter of”

Xtant Medical Holdings, Inc. shareholders approved Approval of Second Amended and Restated 2018 Equity Incentive Plan at the 2022-10-26 meeting.

“Proposal No. 4 - The Xtant Medical Holdings, Inc. Second Amended and Restated 2018 Equity Incentive Plan was approved by the following final voting results: Votes For Votes Against Votes Abstained Broker Non-Votes 82,054,439 809,383 3,618 2,002,504”